… Clinical profile and prognostic significance of natriuretic peptide trajectory following
hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart …

… Evaluating sGC stimulators in a trial with a longer follow-up in patients without worsening
heart failure may better elucidate its effects on mortality. Moreover, the potential anti-…

… with preserved ejection fraction (HFpEF) via cardiac, vascular, and peripheral … worsening
chronic heart failure (HF) requiring hospitalization where, after discharge, cardiovascular …

… injury, including the continuous loss of cardiomyocytes and deterioration of renal function
[8–10]. Evidence exists that the nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic …

… soluble guanylate cyclase (sGC)-cyclic guanosine 3′, 5′-monophosphate pathways in heart
failure and several new drugs that modify guanylate … for decompensated heart failure and …

… role of particulate and soluble guanylate cyclase (pGC and … in heart failure, and several
novel drugs that modify guanylate … heart failure (ADHF) broadly represents new or worsening …

… trials involved patients recently hospitalized with worsening HF, a time during which renal
… In addition, patients with worsening chronic HF (such as those enrolled in the SOCRATES …

… particularly important in the setting of worsening chronic heart failure. The nitric oxide (NO)-…
= soluble guanylate cyclase stimulator in heart failure patients with reduced ejection fraction. …

… agents for heart failure as well [8]. In this review, we aim to discuss the soluble guanylate
cyclase … Poor response to natriuretic peptides leads to worsening of the vicious cycle of …

… novel therapies to treat those with worsening HF symptoms despite optimal or maximally
tolerated medical treatment. This is particularly true in patients with HF with preserved LVEF (…